A public-private council report outlining industry views on Japan’s drug pricing systems drew little discussion at a meeting of the…
BUSINESS
Chugai Halts Dosing of Non-Ambulatory Patients in DMD Gene Therapy Trial after 2 Deaths Overseas
Chugai Pharmaceutical has suspended dosing in Japan of non-ambulatory patients under a global PIII trial of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys (delandistrogene moxeparvovec) following two death cases reported overseas. Subject to the dosing suspension is a non-ambulatory…
To read the full story
Related Article
- Elevidys Coverage Debate to Resume after MHLW Gains Broad Understanding on Safety
October 9, 2025
- MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
- Chugai to Defer Domestic Supply of Elevidys amid Safety Review
July 25, 2025
- Japan Puts a Hold on Coverage Discussions for Elevidys over Safety Concerns
June 19, 2025
- Chugai’s DMD Gene Therapy Snags Conditional Approval in Japan
May 14, 2025
BUSINESS
- Keytruda Still Dominates Japan Drug Market in October: Encise
November 10, 2025
- J&J Files Oral Psoriasis Drug Icotrokinra in Japan
November 10, 2025
- Xarelto AG Logs 9.6 Billion Yen on NHI Basis in April-September: Qol
November 10, 2025
- MSD Seeks Capvaxive Use in High-Risk Children in Japan
November 10, 2025
- MSD Japan Chief Voices Regret over Delay in Routine HPV Shots for Males
November 10, 2025
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
In the complex tapestry of leadership, awareness isn’t just a desirable trait; it’s the bedrock upon which success is built. It’s the lens through which leaders perceive, interpret, and navigate the ever-shifting landscape of their organizations and industries. Without it,…
Japan’s drug wholesalers are facing mounting financial pressure as rising logistics and procurement costs deepen losses on product distribution, even…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…